Why the study?
What factors are associated with the underuse of mineralocorticoid receptor antagonists in patients with HFrEF?
What factors are associated with the underuse of mineralocorticoid receptor antagonists in patients with HFrEF?
MRA underuse in HFrEF is driven by impaired renal function (even when not contraindicated), non-specialist care, and milder disease, highlighting specific targets for quality improvement.
No takes yet. Share an insight, caveat, or question.
Highlights targets to improve MRA uptake in HFrEF; leaves open whether addressing these factors increases appropriate use.
Savarese et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: